TNF and rheumatoid arthritis: BMS-986142, another reversible, covalent BTKi, was evaluated in a phase 2 study; the participants included patients with moderate to severe RA with an inadequate response to methotrexate or methotrexate and who had received up to two TNF inhibitors (Table 2).